Case CCC Developmental Therapeutics Program member Shilpa Gupta, MD, was a keynote speaker at the 4th Clinical Research UroOnc Conference in Beijing. Her invitation follows recent recognition as a European Association of Urology (EAU) Ambassador Award recipient, underscoring her growing international impact in the field of genitourinary oncology.
Gupta, a genitourinary oncologist whose research focuses on clinical and translational advances in GU cancers, joined international colleagues to discuss the rapidly evolving landscape of cancer research and treatment. In her remarks and reflections from the meeting, she highlighted the accelerated pace of clinical innovation—particularly the growing role of antibody-drug conjugate and immunotherapy combinations in bladder cancer—and emphasized how these advances are reshaping global clinical trial strategies.
During her visit, Gupta also toured a newly developed hospital featuring state-of-the-art clinical trial infrastructure, underscoring the expanding capacity for high-impact research collaborations not only in Northeast Ohio, but also worldwide. Her participation reflects Case CCC’s continued engagement in oncology efforts aimed at advancing discovery and improving outcomes for patients with genitourinary cancer.